| Item Type | Name |
|
Academic Article
|
Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside.
|
|
Academic Article
|
Targeting hypoxia-inducible factor-1a (HIF-1a) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab.
|
|
Academic Article
|
A phase I study of hepatic arterial infusion of nab-paclitaxel in combination with intravenous gemcitabine and bevacizumab for patients with advanced cancers and predominant liver metastases.
|
|
Academic Article
|
Phase I clinical trial of bendamustine and bevacizumab for patients with advanced cancer.
|
|
Academic Article
|
Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors.
|
|
Academic Article
|
Exploratory study of hepatic arterial infusion oxaliplatin with systemic 5-fluorouracil/bevacizumab in patients with refractory solid tumor and extensive liver metastases.
|
|
Academic Article
|
Response of lymphangioleiomyomatosis to a mammalian target of rapamycin inhibitor (temsirolimus) -based treatment.
|
|
Academic Article
|
Evaluation of the clinical relevance of body composition parameters in patients with cancer metastatic to the liver treated with hepatic arterial infusion chemotherapy.
|
|
Academic Article
|
Phase I study of the antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity.
|
|
Academic Article
|
Bevacizumab-based treatment in colorectal cancer with a NRAS Q61K mutation.
|
|
Academic Article
|
P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy.
|
|
Academic Article
|
A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver.
|
|
Academic Article
|
Anticoagulation-induced severe bleeding in a patient receiving bevacizumab therapy.
|
|
Academic Article
|
Intraperitoneal and intravenous chemotherapy in peritoneal carcinomatosis.
|
|
Academic Article
|
Dual EGFR inhibition in combination with anti-VEGF treatment: a phase I clinical trial in non-small cell lung cancer.
|
|
Academic Article
|
Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population.
|
|
Academic Article
|
A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies.
|
|
Academic Article
|
Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers.
|
|
Academic Article
|
Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus.
|
|
Academic Article
|
Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors.
|
|
Academic Article
|
A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer.
|
|
Academic Article
|
Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors.
|
|
Academic Article
|
A phase 1b, open-label study of trebananib plus bevacizumab or motesanib in patients with solid tumours.
|
|
Academic Article
|
Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver.
|
|
Academic Article
|
Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer.
|
|
Academic Article
|
Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer
|
|
Academic Article
|
Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus
|
|
Academic Article
|
Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus.
|
|
Academic Article
|
Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab.
|
|
Academic Article
|
Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers.
|
|
Academic Article
|
A phase I clinical trial of hepatic arterial infusion of oxaliplatin and oral capecitabine, with or without intravenous bevacizumab, in patients with advanced cancer and predominant liver involvement.
|
|
Concept
|
Bevacizumab
|
|
Academic Article
|
Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial.
|